NCT02663518 2024-05-10A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsPfizerPhase 1 Terminated249 enrolled 43 charts
NCT01994382 2022-04-05Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLAlexion Pharmaceuticals, Inc.Phase 1/2 Completed260 enrolled 33 charts